Your browser doesn't support javascript.
loading
Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia.
Librizzi, Damiano; Cabanel, Nicole; Zavorotnyy, Maxim; Riehl, Elisabeth; Kircher, Tilo; Luster, Markus; Hooshyar Yousefi, Behrooz.
Afiliação
  • Librizzi D; Department of Nuclear Medicine, Philipps-University of Marburg, 35043 Marburg, Germany.
  • Cabanel N; Department of Psychiatry and Psychotherapy, Philipps-University of Marburg, 35039 Marburg, Germany.
  • Zavorotnyy M; Marburg Center for Mind, Brain and Behavior-MCMBB, University of Marburg, 35032 Marburg, Germany.
  • Riehl E; Department of Psychiatry and Psychotherapy, Philipps-University of Marburg, 35039 Marburg, Germany.
  • Kircher T; Department of Psychiatry and Psychotherapy, Psychiatric Services Aargau, Academic Hospital of the University of Zurich, 5210 Windisch, Switzerland.
  • Luster M; Marburg Center for Mind, Brain and Behavior-MCMBB, University of Marburg, 35032 Marburg, Germany.
  • Hooshyar Yousefi B; Department of Nuclear Medicine, Philipps-University of Marburg, 35043 Marburg, Germany.
Molecules ; 26(5)2021 Feb 26.
Article em En | MEDLINE | ID: mdl-33652938
PET of ß-Amyloid plaques (Aß) using [18F]florbetaben ([18F]FBB) and [18F]fluorodeoxyglucose ([18F]FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer's disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia. The aim of this retrospective analysis was to evaluate clinical relevance of [18F]FBB, [18F]FDG PET and complimentary CSF measurements in patients with suspected dementia. In this study, 40 patients with clinically suspected or history of dementia underwent (1) measurement of Aß peptides, total tau, and p-tau protein levels in the cerebrospinal fluid (CSF) compared with healthy controls (HC); (2) clinical and neuropsychological assessment, which included Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery (CERAD-NAB); (3) [18F]FBB and [18F]FDG PET imaging within an average of 3 weeks. The subjects were within 15 days stratified using PET, CSF measurements as HC, mild cognitive impaired (MCI) and dementia including Alzheimer´s disease. The predictive dementia-related cognitive decline values were supporting the measurements. PET images were evaluated visually and quantitatively using standard uptake value ratios (SUVR). Twenty-one (52.5%) subjects were amyloid-positive (Aß+), with a median neocortical SUVR of 1.80 for AD versus 1.20 relative to the respective 19 (47.5 %) amyloid-negative (Aß-) subjects. Moreover, the [18F]FDG and [18F]FBB confirmed within a sub-group of 10 patients a good complimentary role by correlation between amyloid pathology and brain glucose metabolism in 8 out of 10 subjects. The results suggest the clinical relevance for [18F]FBB combined with [18F]FDG PET retention and CFS measurements serving the management of our patients with dementia. Therefore, [18F]FBB combined with [18F]FDG PET is a helpful tool for differential diagnosis, and supports the patients' management as well as treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Demência / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Demência / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article